open access

Vol 23, No 5 (2018)
Original research articles
Published online: 2018-09-01
Submitted: 2018-01-06
Get Citation

Interinstitutional patient transfers between rapid chemotherapy cycles were feasible to utilize proton beam therapy for pediatric Ewing sarcoma family of tumors

Tomohei Nakao, Hiroko Fukushima, Takashi Fukushima, Ryoko Suzuki, Sho Hosaka, Yuni Yamaki, Chie Kobayashi, Atsushi Iwabuchi, Kazuo Imagawa, Aiko Sakai, Toko Shinkai, Kouji Masumoto, Shingo Sakashita, Tomohiko Masumoto, Masashi Mizumoto, Ryo Sumazaki, Hideyuki Sakurai
DOI: 10.1016/j.rpor.2018.08.006
·
Rep Pract Oncol Radiother 2018;23(5):442-450.

open access

Vol 23, No 5 (2018)
Original research articles
Published online: 2018-09-01
Submitted: 2018-01-06

Abstract

Aim

To assess the feasibility of transferring to the University of Tsukuba Hospital for proton beam therapy (PBT) during intensive chemotherapy in children with Ewing sarcoma family of tumors (ESFT) who had been diagnosed and started their first-line treatment at prefectural or regional centers for pediatric oncology.

Background

The treatment of ESFT relies on a multidisciplinary approach using intensive neoadjuvant and adjuvant chemotherapies with surgery and radiotherapy. Multi-agent chemotherapy comprising vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide (VDC-IE) is widely used for ESFT, and the interval between each course is very important for maintaining the intensity and effect of chemotherapy.

Materials and methods

Clinical information of patients who received PBT and VDC-IE between April 2009 and May 2016 was collected retrospectively. The intervals between each course of VDC-IE and adverse events were assessed.

Results

Fifteen patients were evaluated. No delays in the intervals of chemotherapy due to transfer were observed. There were no adverse events caused during/just after transfer and no increases in adverse events. The estimated 4-year overall and event-free survival rates were 94.6% and 84.8%, respectively.

Discussion

Although the results of efficacy are preliminary, survival rates were comparable with past studies. More experience and follow-up are required to further assess the efficacy of PBT for patients with ESFT.

Conclusion

Multidisciplinary therapy for children with ESFT involving transfer to our hospital for PBT during VDC-IE was feasible without treatment delay or an increase in adverse events.

Abstract

Aim

To assess the feasibility of transferring to the University of Tsukuba Hospital for proton beam therapy (PBT) during intensive chemotherapy in children with Ewing sarcoma family of tumors (ESFT) who had been diagnosed and started their first-line treatment at prefectural or regional centers for pediatric oncology.

Background

The treatment of ESFT relies on a multidisciplinary approach using intensive neoadjuvant and adjuvant chemotherapies with surgery and radiotherapy. Multi-agent chemotherapy comprising vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide (VDC-IE) is widely used for ESFT, and the interval between each course is very important for maintaining the intensity and effect of chemotherapy.

Materials and methods

Clinical information of patients who received PBT and VDC-IE between April 2009 and May 2016 was collected retrospectively. The intervals between each course of VDC-IE and adverse events were assessed.

Results

Fifteen patients were evaluated. No delays in the intervals of chemotherapy due to transfer were observed. There were no adverse events caused during/just after transfer and no increases in adverse events. The estimated 4-year overall and event-free survival rates were 94.6% and 84.8%, respectively.

Discussion

Although the results of efficacy are preliminary, survival rates were comparable with past studies. More experience and follow-up are required to further assess the efficacy of PBT for patients with ESFT.

Conclusion

Multidisciplinary therapy for children with ESFT involving transfer to our hospital for PBT during VDC-IE was feasible without treatment delay or an increase in adverse events.

Get Citation

Keywords

PBT; ESFT; VDC-IE; UTH; EFS; OS; DFS; Ewing sarcoma family of tumors (ESFT); Proton beam therapy (PBT); Multidisciplinary therapy; Multi-institutional; Pediatric

About this article
Title

Interinstitutional patient transfers between rapid chemotherapy cycles were feasible to utilize proton beam therapy for pediatric Ewing sarcoma family of tumors

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 23, No 5 (2018)

Pages

442-450

Published online

2018-09-01

DOI

10.1016/j.rpor.2018.08.006

Bibliographic record

Rep Pract Oncol Radiother 2018;23(5):442-450.

Keywords

PBT
ESFT
VDC-IE
UTH
EFS
OS
DFS
Ewing sarcoma family of tumors (ESFT)
Proton beam therapy (PBT)
Multidisciplinary therapy
Multi-institutional
Pediatric

Authors

Tomohei Nakao
Hiroko Fukushima
Takashi Fukushima
Ryoko Suzuki
Sho Hosaka
Yuni Yamaki
Chie Kobayashi
Atsushi Iwabuchi
Kazuo Imagawa
Aiko Sakai
Toko Shinkai
Kouji Masumoto
Shingo Sakashita
Tomohiko Masumoto
Masashi Mizumoto
Ryo Sumazaki
Hideyuki Sakurai

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl